Germany · Delayed Price · Currency is EUR NextCell Pharma AB Statistics
Total Valuation
FRA:65G has a market cap or net worth of EUR 7.71 million. The enterprise value is 4.18 million.
| Market Cap | 7.71M |
| Enterprise Value | 4.18M |
Important Dates
The next estimated earnings date is Thursday, January 29, 2026.
| Earnings Date | Jan 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 111.39M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +87.22% |
| Shares Change (QoQ) | +50.15% |
| Owned by Insiders (%) | 8.72% |
| Owned by Institutions (%) | 24.80% |
| Float | 89.03M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.73 |
| PB Ratio | 1.29 |
| P/TBV Ratio | 1.29 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.32 |
| EV / Sales | 4.15 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -1.08 |
Financial Position
The company has a current ratio of 10.02
| Current Ratio | 10.02 |
| Quick Ratio | 8.05 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -20,623.64 |
Financial Efficiency
Return on equity (ROE) is -52.46% and return on invested capital (ROIC) is -33.48%.
| Return on Equity (ROE) | -52.46% |
| Return on Assets (ROA) | -28.39% |
| Return on Invested Capital (ROIC) | -33.48% |
| Return on Capital Employed (ROCE) | -50.33% |
| Revenue Per Employee | 41,595 |
| Profits Per Employee | -132,115 |
| Employee Count | 24 |
| Asset Turnover | 0.14 |
| Inventory Turnover | 17.23 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -56.62% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -56.62% |
| 50-Day Moving Average | 0.07 |
| 200-Day Moving Average | 0.11 |
| Relative Strength Index (RSI) | 26.74 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, FRA:65G had revenue of EUR 998,291 and -3.17 million in losses. Loss per share was -0.04.
| Revenue | 998,291 |
| Gross Profit | 150,452 |
| Operating Income | -3.24M |
| Pretax Income | -3.17M |
| Net Income | -3.17M |
| EBITDA | -3.01M |
| EBIT | -3.24M |
| Loss Per Share | -0.04 |
Balance Sheet
The company has 3.49 million in cash and n/a in debt, giving a net cash position of 3.49 million.
| Cash & Cash Equivalents | 3.49M |
| Total Debt | n/a |
| Net Cash | 3.49M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 5.99M |
| Book Value Per Share | 0.05 |
| Working Capital | 4.42M |
Cash Flow
In the last 12 months, operating cash flow was -3.51 million and capital expenditures -377,215, giving a free cash flow of -3.88 million.
| Operating Cash Flow | -3.51M |
| Capital Expenditures | -377,215 |
| Free Cash Flow | -3.88M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 15.07% |
| Operating Margin | -324.35% |
| Pretax Margin | -317.62% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:65G does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -87.22% |
| Shareholder Yield | -87.22% |
| Earnings Yield | -41.11% |
| FCF Yield | -50.36% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
FRA:65G has an Altman Z-Score of 4.18 and a Piotroski F-Score of 3.
| Altman Z-Score | 4.18 |
| Piotroski F-Score | 3 |